# Inhibikase Therapeutics Inc. (IKT) — Operating Income

## Annual Operating Income (USD)

| Year | Operating Income |
| --- | --- |
| 2024 | -$29M |
| 2023 | -$20M |
| 2022 | -$18M |
| 2021 | -$15M |
| 2020 | -$3M |

## Quarterly Operating Income (USD)

| Quarter | Operating Income |
| --- | --- |
| 2026-03-31 | -$18M |
| 2025-09-30 | -$13M |
| 2025-06-30 | -$11M |
| 2025-03-31 | -$15M |
| 2024-09-30 | -$6M |
| 2024-06-30 | -$5M |
| 2024-03-31 | -$5M |
| 2023-09-30 | -$5M |
| 2023-06-30 | -$6M |
| 2023-03-31 | -$5M |
| 2022-09-30 | -$5M |
| 2022-06-30 | -$5M |
| 2022-03-31 | -$5M |
| 2021-09-30 | -$4M |
| 2021-06-30 | -$3M |
| 2021-03-31 | -$3M |
| 2020-09-30 | -$663,709 |
| 2020-06-30 | -$413,921 |
| 2020-03-31 | -$540,015 |

Source: [MarketCapTrends](https://marketcaptrends.com/company/IKT/operating-income)